Compare Natera Inc. Common Stock (NTRA) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Oracle Corporation — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Oracle Corporation trades at $128.71 (market cap $434.11B). The key difference: Oracle Corporation is far larger — about 7.6× Natera Inc. Common Stock's market cap, and Oracle Corporation pays a 1.4% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Oracle Corporation for 73 Days on average.
| NTRA | ORCL | |
|---|---|---|
Market Cap | $57.03B | $434.11B |
Volume | 1,131,157 | 25,917,551 |
Sector | Health | Technology |
52-Week High | $425.64 | $313.00 |
52-Week Low | $179.42 | $114.99 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $56.18B | $557.92B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Oracle (ORCL) trades at $137.40, down 2.92% on the day amid a bearish technical signal, though it has consistently beaten earnings estimates in recent quarters. Revenue grew to $57.40B in 2025 with a net income margin of 26.36%, while analyst consensus remains strongly bullish with a $236.52 price target. Recent news highlights strong AI cloud demand and restructuring efforts to support growth.
The outlook is positive given robust fundamentals and AI-driven revenue acceleration, but risks include high debt levels, competitive pressures, and market volatility. The stock presents a long-term opportunity if execution on AI infrastructure continues, though near-term price weakness reflects investor caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
